{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:35:48Z","timestamp":1778600148638,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Androgen deprivation therapies aimed to target prostate cancer (PrCa) are only partially successful given the occurrence of neuroendocrine PrCa (NEPrCa), a highly aggressive and highly metastatic form of PrCa, for which there is no effective therapeutic approach. Our group has demonstrated that while absent in prostate adenocarcinoma, the \u03b1V\u03b23 integrin expression is increased during PrCa progression toward NEPrCa. Here, we show a novel pathway activated by \u03b1V\u03b23 that promotes NE differentiation (NED). This novel pathway requires the expression of a GPI-linked surface molecule, NgR2, also known as Nogo-66 receptor homolog 1. We show here that NgR2 is upregulated by \u03b1V\u03b23, to which it associates; we also show that it promotes NED and anchorage-independent growth, as well as a motile phenotype of PrCa cells. Given our observations that high levels of \u03b1V\u03b23 and, as shown here, of NgR2 are detected in human and mouse NEPrCa, our findings appear to be highly relevant to this aggressive and metastatic subtype of PrCa. This study is novel because NgR2 role has only minimally been investigated in cancer and has instead predominantly been analyzed in neurons. These data thus pave new avenues toward a comprehensive mechanistic understanding of integrin-directed signaling during PrCa progression toward a NE phenotype.<\/jats:p>","DOI":"10.1038\/s41598-022-21711-5","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T15:08:49Z","timestamp":1667833729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The NOGO receptor NgR2, a novel \u03b1V\u03b23 integrin effector, induces neuroendocrine differentiation in prostate cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Fabio","family":"Quaglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv Ram","family":"Krishn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Sossey-Alaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka Shailendra","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elzbieta","family":"Pluskota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pyung Hun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McCue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew V.","family":"Kossenkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Goodrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Yu","family":"Ku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William K.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Corey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Klose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Bandtlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario C.","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward F.","family":"Plow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia R.","family":"Languino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"21711_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.579068","volume":"11","author":"CY Su","year":"2020","unstructured":"Su, C. Y. et al. The biological functions and clinical applications of integrins in cancers. Front. Pharmacol. 11, 579068. https:\/\/doi.org\/10.3389\/fphar.2020.579068 (2020).","journal-title":"Front. Pharmacol."},{"key":"21711_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071711","author":"BS Ludwig","year":"2021","unstructured":"Ludwig, B. S., Kessler, H., Kossatz, S. & Reuning, U. RGD-binding integrins revisited: How recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13071711 (2021).","journal-title":"Cancers (Basel)"},{"key":"21711_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9\u201322. https:\/\/doi.org\/10.1038\/nrc2748 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"21711_CR4","first-page":"1655","volume":"59","author":"DQ Zheng","year":"1999","unstructured":"Zheng, D. Q., Woodard, A. S., Fornaro, M., Tallini, G. & Languino, L. R. Prostatic carcinoma cell migration via \u03b1V\u03b23 integrin is modulated by a focal adhesion kinase pathway. Cancer Res. 59, 1655\u20131664 (1999).","journal-title":"Cancer Res."},{"key":"21711_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1101\/gad.469408","volume":"22","author":"E Montanez","year":"2008","unstructured":"Montanez, E. et al. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev. 22, 1325\u20131330. https:\/\/doi.org\/10.1101\/gad.469408 (2008).","journal-title":"Genes Dev."},{"key":"21711_CR6","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.cub.2013.09.050","volume":"23","author":"F Ye","year":"2013","unstructured":"Ye, F. et al. The mechanism of kindlin-mediated activation of integrin \u03b1IIb\u03b23. Curr. Biol. 23, 2288\u20132295. https:\/\/doi.org\/10.1016\/j.cub.2013.09.050 (2013).","journal-title":"Curr. Biol."},{"key":"21711_CR7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.10130","volume":"5","author":"M Theodosiou","year":"2016","unstructured":"Theodosiou, M. et al. Kindlin-2 cooperates with talin to activate integrins and induces cell spreading by directly binding paxillin. Elife 5, e10130. https:\/\/doi.org\/10.7554\/eLife.10130 (2016).","journal-title":"Elife"},{"key":"21711_CR8","doi-asserted-by":"publisher","first-page":"30370","DOI":"10.1074\/jbc.C110.134247","volume":"285","author":"K Bledzka","year":"2010","unstructured":"Bledzka, K. et al. Tyrosine phosphorylation of integrin \u03b23 regulates kindlin-2 binding and integrin activation. J. Biol. Chem. 285, 30370\u201330374. https:\/\/doi.org\/10.1074\/jbc.C110.134247 (2010).","journal-title":"J. Biol. Chem."},{"key":"21711_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1083\/jcb.200710196","volume":"181","author":"YQ Ma","year":"2008","unstructured":"Ma, Y. Q., Qin, J., Wu, C. & Plow, E. F. Kindlin-2 (Mig-2): A co-activator of \u03b23 integrins. J. Cell Biol. 181, 439\u2013446. https:\/\/doi.org\/10.1083\/jcb.200710196 (2008).","journal-title":"J. Cell Biol."},{"key":"21711_CR10","doi-asserted-by":"publisher","first-page":"24585","DOI":"10.1074\/jbc.M111.336743","volume":"287","author":"K Bledzka","year":"2012","unstructured":"Bledzka, K. et al. Spatial coordination of kindlin-2 with talin head domain in interaction with integrin \u03b2 cytoplasmic tails. J. Biol. Chem. 287, 24585\u201324594. https:\/\/doi.org\/10.1074\/jbc.M111.336743 (2012).","journal-title":"J. Biol. Chem."},{"key":"21711_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0092-8674(03)00163-6","volume":"113","author":"Y Tu","year":"2003","unstructured":"Tu, Y., Wu, S., Shi, X., Chen, K. & Wu, C. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell 113, 37\u201347. https:\/\/doi.org\/10.1016\/s0092-8674(03)00163-6 (2003).","journal-title":"Cell"},{"key":"21711_CR12","doi-asserted-by":"publisher","first-page":"1761072","DOI":"10.1080\/20013078.2020.1761072","volume":"9","author":"F Quaglia","year":"2020","unstructured":"Quaglia, F. et al. Small extracellular vesicles modulated by \u03b1V\u03b23 integrin induce neuroendocrine differentiation in recipient cancer cells. J. Extracell. Vesicles 9, 1761072. https:\/\/doi.org\/10.1080\/20013078.2020.1761072 (2020).","journal-title":"J. Extracell. Vesicles"},{"key":"21711_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244985","volume":"16","author":"F Quaglia","year":"2021","unstructured":"Quaglia, F. et al. Differential expression of \u03b1V\u03b23 and \u03b1V\u03b26 integrins in prostate cancer progression. PLoS ONE 16, e0244985. https:\/\/doi.org\/10.1371\/journal.pone.0244985 (2021).","journal-title":"PLoS ONE"},{"key":"21711_CR14","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1158\/0008-5472.CAN-16-0543","volume":"76","author":"H Lu","year":"2016","unstructured":"Lu, H. et al. \u03b1V\u03b26 integrin promotes castrate-resistant prostate cancer through JNK1-mediated activation of androgen receptor. Cancer Res. 76, 5163\u20135174. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0543 (2016).","journal-title":"Cancer Res."},{"key":"21711_CR15","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran, H. et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin. Cancer Res. 25, 6916\u20136924. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1423 (2019).","journal-title":"Clin. Cancer Res."},{"key":"21711_CR16","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA 116, 11428\u201311436. https:\/\/doi.org\/10.1073\/pnas.1902651116 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"21711_CR17","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/jco.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J. Clin. Oncol. 36, 2492\u20132503. https:\/\/doi.org\/10.1200\/jco.2017.77.6880 (2018).","journal-title":"J. Clin. Oncol."},{"key":"21711_CR18","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/1078-0432.Ccr-13-3309","volume":"20","author":"H Beltran","year":"2014","unstructured":"Beltran, H. et al. Aggressive variants of castration resistant prostate cancer. Clin. Cancer Res. 20, 2846\u20132850. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-3309 (2014).","journal-title":"Clin. Cancer Res."},{"key":"21711_CR19","first-page":"273","volume":"2","author":"V Parimi","year":"2014","unstructured":"Parimi, V., Goyal, R., Poropatich, K. & Yang, X. J. Neuroendocrine differentiation of prostate cancer: A review. Am. J. Clin. Exp. Urol. 2, 273\u2013285 (2014).","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"21711_CR20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298\u2013305. https:\/\/doi.org\/10.1038\/nm.4045 (2016).","journal-title":"Nat. Med."},{"key":"21711_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0094-0143(05)70068-9","volume":"26","author":"J Kim","year":"1999","unstructured":"Kim, J. & Logothetis, C. J. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol. Clin. N. Am. 26, 281\u2013290. https:\/\/doi.org\/10.1016\/s0094-0143(05)70068-9 (1999).","journal-title":"Urol. Clin. N. Am."},{"key":"21711_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146827","volume":"6","author":"WN Brennen","year":"2021","unstructured":"Brennen, W. N. et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight 6, e146827. https:\/\/doi.org\/10.1172\/jci.insight.146827 (2021).","journal-title":"JCI Insight"},{"key":"21711_CR23","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1523\/JNEUROSCI.4935-08.2009","volume":"29","author":"LA Robak","year":"2009","unstructured":"Robak, L. A. et al. Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: Development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition. J. Neurosci. 29, 5768\u20135783. https:\/\/doi.org\/10.1523\/JNEUROSCI.4935-08.2009 (2009).","journal-title":"J. Neurosci."},{"key":"21711_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1046\/j.1471-4159.2003.01710.x","volume":"85","author":"V Pignot","year":"2003","unstructured":"Pignot, V. et al. Characterization of two novel proteins, NgRH1 and NgRH2, structurally and biochemically homologous to the Nogo-66 receptor. J. Neurochem. 85, 717\u2013728. https:\/\/doi.org\/10.1046\/j.1471-4159.2003.01710.x (2003).","journal-title":"J. Neurochem."},{"key":"21711_CR25","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/pro.597","volume":"20","author":"M Semavina","year":"2011","unstructured":"Semavina, M. et al. Crystal structure of the Nogo-receptor-2. Protein Sci. 20, 684\u2013689. https:\/\/doi.org\/10.1002\/pro.597 (2011).","journal-title":"Protein Sci."},{"key":"21711_CR26","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1093\/emboj\/cdg325","volume":"22","author":"WA Barton","year":"2003","unstructured":"Barton, W. A. et al. Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. Embo J. 22, 3291\u20133302. https:\/\/doi.org\/10.1093\/emboj\/cdg325 (2003).","journal-title":"Embo J."},{"key":"21711_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nature01176","volume":"420","author":"KC Wang","year":"2002","unstructured":"Wang, K. C., Kim, J. A., Sivasankaran, R., Segal, R. & He, Z. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420, 74\u201378. https:\/\/doi.org\/10.1038\/nature01176 (2002).","journal-title":"Nature"},{"key":"21711_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nn1188","volume":"7","author":"S Mi","year":"2004","unstructured":"Mi, S. et al. LINGO-1 is a component of the Nogo-66 receptor\/p75 signaling complex. Nat. Neurosci. 7, 221\u2013228. https:\/\/doi.org\/10.1038\/nn1188 (2004).","journal-title":"Nat. Neurosci."},{"key":"21711_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.tins.2008.02.002","volume":"31","author":"S David","year":"2008","unstructured":"David, S., Fry, E. J. & Lopez-Vales, R. Novel roles for Nogo receptor in inflammation and disease. Trends Neurosci. 31, 221\u2013226. https:\/\/doi.org\/10.1016\/j.tins.2008.02.002 (2008).","journal-title":"Trends Neurosci."},{"key":"21711_CR30","doi-asserted-by":"publisher","first-page":"7447","DOI":"10.1038\/s41388-019-0963-7","volume":"38","author":"JH Svensmark","year":"2019","unstructured":"Svensmark, J. H. & Brakebusch, C. Rho GTPases in cancer: Friend or foe?. Oncogene 38, 7447\u20137456. https:\/\/doi.org\/10.1038\/s41388-019-0963-7 (2019).","journal-title":"Oncogene"},{"key":"21711_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1210\/me.2011-1130","volume":"26","author":"LJ Schmidt","year":"2012","unstructured":"Schmidt, L. J. et al. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol. Endocrinol. 26, 716\u2013735. https:\/\/doi.org\/10.1210\/me.2011-1130 (2012).","journal-title":"Mol. Endocrinol."},{"key":"21711_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/pros.23939","volume":"80","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer. Prostate 80, 256\u2013266. https:\/\/doi.org\/10.1002\/pros.23939 (2020).","journal-title":"Prostate"},{"key":"21711_CR33","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1038\/sj.onc.1209586","volume":"25","author":"R Zheng","year":"2006","unstructured":"Zheng, R. et al. Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. Oncogene 25, 5942\u20135952. https:\/\/doi.org\/10.1038\/sj.onc.1209586 (2006).","journal-title":"Oncogene"},{"key":"21711_CR34","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/ijlh.13644","volume":"43","author":"Y Osman","year":"2021","unstructured":"Osman, Y. et al. Functional multigenic variations associated with hodgkin lymphoma. Int. J. Lab. Hematol. 43, 1472\u20131482. https:\/\/doi.org\/10.1111\/ijlh.13644 (2021).","journal-title":"Int. J. Lab. Hematol."},{"key":"21711_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00109-017-1618-1","volume":"96","author":"JY He","year":"2018","unstructured":"He, J. Y. et al. Overexpression of Nogo receptor 3 (NgR3) correlates with poor prognosis and contributes to the migration of epithelial cells of nasopharyngeal carcinoma patients. J. Mol. Med. (Berl) 96, 265\u2013279. https:\/\/doi.org\/10.1007\/s00109-017-1618-1 (2018).","journal-title":"J. Mol. Med. (Berl)"},{"key":"21711_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/brain\/awaa408","volume":"144","author":"JH Hong","year":"2021","unstructured":"Hong, J. H. et al. Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma. Brain 144, 636\u2013654. https:\/\/doi.org\/10.1093\/brain\/awaa408 (2021).","journal-title":"Brain"},{"key":"21711_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.matbio.2018.08.004","volume":"77","author":"SR Krishn","year":"2019","unstructured":"Krishn, S. R. et al. Prostate cancer sheds the \u03b1v\u03b23 integrin in vivo through exosomes. Matrix Biol. 77, 41\u201357. https:\/\/doi.org\/10.1016\/j.matbio.2018.08.004 (2019).","journal-title":"Matrix Biol."},{"key":"21711_CR38","doi-asserted-by":"publisher","first-page":"1763594","DOI":"10.1080\/20013078.2020.1763594","volume":"9","author":"SR Krishn","year":"2020","unstructured":"Krishn, S. R. et al. The \u03b1V\u03b26 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis. J. Extracell. Vesicles 9, 1763594. https:\/\/doi.org\/10.1080\/20013078.2020.1763594 (2020).","journal-title":"J. Extracell. Vesicles"},{"key":"21711_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10549-013-2753-1","volume":"142","author":"MA Taylor","year":"2013","unstructured":"Taylor, M. A. et al. Upregulated WAVE3 expression is essential for TGF-\u03b2-mediated EMT and metastasis of triple-negative breast cancer cells. Breast Cancer Res. Treat. 142, 341\u2013353. https:\/\/doi.org\/10.1007\/s10549-013-2753-1 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"21711_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41419-019-1774-z","volume":"10","author":"K Sossey-Alaoui","year":"2019","unstructured":"Sossey-Alaoui, K., Pluskota, E., Szpak, D. & Plow, E. F. The Kindlin2-p53-SerpinB2 signaling axis is required for cellular senescence in breast cancer. Cell Death Dis. 10, 539. https:\/\/doi.org\/10.1038\/s41419-019-1774-z (2019).","journal-title":"Cell Death Dis."},{"key":"21711_CR41","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1158\/0008-5472.Can-16-2337","volume":"77","author":"K Sossey-Alaoui","year":"2017","unstructured":"Sossey-Alaoui, K. et al. Kindlin-2 regulates the growth of breast cancer tumors by activating CSF-1-mediated macrophage infiltration. Cancer Res. 77, 5129\u20135141. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-2337 (2017).","journal-title":"Cancer Res."},{"key":"21711_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.Cd-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487\u2013495. https:\/\/doi.org\/10.1158\/2159-8290.Cd-11-0130 (2011).","journal-title":"Cancer Discov."},{"key":"21711_CR43","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque, M. P. et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J. Clin. Invest. 129, 4492\u20134505. https:\/\/doi.org\/10.1172\/JCI128212 (2019).","journal-title":"J. Clin. Invest."},{"key":"21711_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383. https:\/\/doi.org\/10.1126\/science.aah4199 (2017).","journal-title":"Science"},{"key":"21711_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005218","volume":"4","author":"V W\u00f6rter","year":"2009","unstructured":"W\u00f6rter, V. et al. Inhibitory activity of myelin-associated glycoprotein on sensory neurons is largely independent of NgR1 and NgR2 and resides within Ig-Like domains 4 and 5. PLoS ONE 4, e5218. https:\/\/doi.org\/10.1371\/journal.pone.0005218 (2009).","journal-title":"PLoS ONE"},{"key":"21711_CR46","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1523\/jneurosci.3094-13.2014","volume":"34","author":"BE B\u00e4umer","year":"2014","unstructured":"B\u00e4umer, B. E. et al. Nogo receptor homolog NgR2 expressed in sensory DRG neurons controls epidermal innervation by interaction with Versican. J. Neurosci. 34, 1633\u20131646. https:\/\/doi.org\/10.1523\/jneurosci.3094-13.2014 (2014).","journal-title":"J. Neurosci."},{"key":"21711_CR47","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1073\/pnas.0409026102","volume":"102","author":"B Zheng","year":"2005","unstructured":"Zheng, B. et al. Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc. Natl. Acad. Sci. USA 102, 1205\u20131210. https:\/\/doi.org\/10.1073\/pnas.0409026102 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"21711_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1385\/1-59745-213-0:267","volume":"129","author":"DA Soloviev","year":"2006","unstructured":"Soloviev, D. A., Pluskota, E. & Plow, E. F. Cell adhesion and migration assays. Methods Mol. Med. 129, 267\u2013278. https:\/\/doi.org\/10.1385\/1-59745-213-0:267 (2006).","journal-title":"Methods Mol. Med."},{"key":"21711_CR49","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1182\/blood-2010-11-321182","volume":"117","author":"E Pluskota","year":"2011","unstructured":"Pluskota, E. et al. The integrin coactivator kindlin-2 plays a critical role in angiogenesis in mice and zebrafish. Blood 117, 4978\u20134987. https:\/\/doi.org\/10.1182\/blood-2010-11-321182 (2011).","journal-title":"Blood"},{"key":"21711_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the cancer cell line encyclopedia. Nature 569, 503\u2013508. https:\/\/doi.org\/10.1038\/s41586-019-1186-3 (2019).","journal-title":"Nature"},{"key":"21711_CR51","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/pros.23313","volume":"77","author":"HM Nguyen","year":"2017","unstructured":"Nguyen, H. M. et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. Prostate 77, 654\u2013671. https:\/\/doi.org\/10.1002\/pros.23313 (2017).","journal-title":"Prostate"},{"key":"21711_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/neo.121550","volume":"15","author":"JM Mosquera","year":"2013","unstructured":"Mosquera, J. M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1\u201310. https:\/\/doi.org\/10.1593\/neo.121550 (2013).","journal-title":"Neoplasia"},{"key":"21711_CR53","first-page":"1359","volume":"63","author":"JC Hodge","year":"2003","unstructured":"Hodge, J. C., Bub, J., Kaul, S., Kajdacsy-Balla, A. & Lindholm, P. F. Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res. 63, 1359\u20131364 (2003).","journal-title":"Cancer Res."},{"key":"21711_CR54","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1083\/jcb.200301080","volume":"162","author":"CI Dubreuil","year":"2003","unstructured":"Dubreuil, C. I., Winton, M. J. & McKerracher, L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J. Cell Biol. 162, 233\u2013243. https:\/\/doi.org\/10.1083\/jcb.200301080 (2003).","journal-title":"J. Cell Biol."},{"key":"21711_CR55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1083\/jcb.201501006","volume":"213","author":"K Bledzka","year":"2016","unstructured":"Bledzka, K. et al. Kindlin-2 directly binds actin and regulates integrin outside-in signaling. J. Cell Biol. 213, 97\u2013108. https:\/\/doi.org\/10.1083\/jcb.201501006 (2016).","journal-title":"J. Cell Biol."},{"key":"21711_CR56","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/s41467-017-01573-6","volume":"8","author":"G Restivo","year":"2017","unstructured":"Restivo, G. et al. The low neurotrophin receptor CD271 regulates phenotype switching in melanoma. Nat. Commun. 8, 1988. https:\/\/doi.org\/10.1038\/s41467-017-01573-6 (2017).","journal-title":"Nat. Commun."},{"key":"21711_CR57","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/s43018-021-00272-y","volume":"2","author":"S Garc\u00eda-Silva","year":"2021","unstructured":"Garc\u00eda-Silva, S. et al. Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. Nat. Cancer 2, 1387\u20131405. https:\/\/doi.org\/10.1038\/s43018-021-00272-y (2021).","journal-title":"Nat. Cancer"},{"key":"21711_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jnci\/djp456","volume":"102","author":"Z Gil","year":"2010","unstructured":"Gil, Z. et al. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J. Natl. Cancer Inst. 102, 107\u2013118. https:\/\/doi.org\/10.1093\/jnci\/djp456 (2010).","journal-title":"J. Natl. Cancer Inst."},{"key":"21711_CR59","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1523\/JNEUROSCI.4464-04.2005","volume":"25","author":"K Venkatesh","year":"2005","unstructured":"Venkatesh, K. et al. The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. J. Neurosci. 25, 808\u2013822. https:\/\/doi.org\/10.1523\/JNEUROSCI.4464-04.2005 (2005).","journal-title":"J. Neurosci."},{"key":"21711_CR60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/mcne.1996.0007","volume":"7","author":"ME DeBellard","year":"1996","unstructured":"DeBellard, M. E., Tang, S., Mukhopadhyay, G., Shen, Y. J. & Filbin, M. T. Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein. Mol. Cell Neurosci. 7, 89\u2013101. https:\/\/doi.org\/10.1006\/mcne.1996.0007 (1996).","journal-title":"Mol. Cell Neurosci."},{"key":"21711_CR61","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/0896-6273(94)90042-6","volume":"13","author":"G Mukhopadhyay","year":"1994","unstructured":"Mukhopadhyay, G., Doherty, P., Walsh, F. S., Crocker, P. R. & Filbin, M. T. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 13, 757\u2013767. https:\/\/doi.org\/10.1016\/0896-6273(94)90042-6 (1994).","journal-title":"Neuron"},{"key":"21711_CR62","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/1541-7786.Mcr-16-0447","volume":"15","author":"Y Jiang","year":"2017","unstructured":"Jiang, Y., Dai, J., Yao, Z., Shelley, G. & Keller, E. T. Abituzumab targeting of \u03b1V-class integrins inhibits prostate cancer progression. Mol. Cancer Res. 15, 875\u2013883. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-16-0447 (2017).","journal-title":"Mol. Cancer Res."},{"key":"21711_CR63","first-page":"2625","volume":"4","author":"G Gasparini","year":"1998","unstructured":"Gasparini, G. et al. Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer. Clin. Cancer Res. 4, 2625\u20132634 (1998).","journal-title":"Clin. Cancer Res."},{"key":"21711_CR64","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1172\/jci5487","volume":"103","author":"KM Hodivala-Dilke","year":"1999","unstructured":"Hodivala-Dilke, K. M. et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103, 229\u2013238. https:\/\/doi.org\/10.1172\/jci5487 (1999).","journal-title":"J. Clin. Invest."},{"key":"21711_CR65","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.3892\/mmr.2017.6850","volume":"16","author":"X Guo","year":"2017","unstructured":"Guo, X. & Liu, X. Nogo receptor knockdown and ciliary neurotrophic factor attenuate diabetic retinopathy in streptozotocin-induced diabetic rats. Mol. Med. Rep. 16, 2030\u20132036. https:\/\/doi.org\/10.3892\/mmr.2017.6850 (2017).","journal-title":"Mol. Med. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21711-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21711-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21711-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T15:16:35Z","timestamp":1667834195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21711-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21711"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21711-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"27 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HB has served as consultant\/advisory board member for Janssen, Sanofi Genzyme, Astellas, Astra Zeneca, Merck, Pfizer, Foundation Medicine, Blue Earth, and has received research funding from Janssen Oncology (Inst), AbbVie\/Stemcentrx (Inst), Eli Lilly (Inst), Millennium Pharmaceuticals (Inst). DWG has a sponsored research agreement with Celgene\/BMS. EC received research funding from, Janssen Research and Development, Bayer Pharmaceuticals, KronosBio, Forma Pharmaceutics Foghorn, Gilead, Sanofi, AbbVie, and GSK (all Inst.). All other authors have declared that no relevant conflict of interest exists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18879"}}